Abstract-The aim of the present study was to analyze the possible involvement of vasoconstrictors prostanoids on the reduced endothelium-dependent relaxations produced by chronic administration of aldosterone in Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). For this purpose, acetylcholine (ACh) relaxations in aortic segments from both strains were analyzed in absence and presence of the cyclooxygenase-1 (COX-1) and COX-2 inhibitor indomethacin, the specific COX-2 inhibitor NS-398, the TP receptor antagonist (SQ 29 548), the thromboxane A 2 (TXA 2 ) synthase inhibitor furegrelate, and the prostacyclin (PGI 2 ) synthesis inhibitor tranylcypromine (TCP). In addition, COX-2 protein expression was studied by Western blot analysis. Release of prostaglandin E 2 (PGE 2 ) and the metabolites of PGF 2␣ , TXA 2 , and PGI 2 , 13,14-dihydro-15-keto PGF 2a , TXB 2 , and 6-keto-PGF 1␣ , respectively, were measured. Treatment with aldosterone did not modify blood pressure levels in any strain. However, aldosterone markedly reduced (PϽ0.05) ACh-induced relaxations in segments from both strains in a similar extent. Indomethacin, NS-398, SQ 29 548, and TCP enhanced (PϽ0.05) ACh relaxations in both strains treated with aldosterone. Aortic COX-2 protein expression was higher in both strains of rats treated with aldosterone. In normotensive animals, aldosterone increases the ACh-stimulated aortic production of 13,14-dihydro-15-keto PGF 2a, PGE 2 , and 6-keto-PGF 1␣ (PϽ0.05). In SHR, ACh only increased the 6-keto-PGF 1␣ production (PϽ0.05). It could be concluded that chronic treatment with aldosterone was able to produce endothelial dysfunction through COX-2 activation in normotensive and hypertensive conditions. PGI 2 seems to be the main factor accounting for endothelial dysfunction in hypertensive rats, whereas other prostanoids besides PGI 2 appear to be involved in endothelial dysfunction under normotensive conditions. Key Words: aldosterone Ⅲ endothelium Ⅲ prostacyclin Ⅲ normotension Ⅲ hypertension A ldosterone is a mineralocorticoid that participates in electrolyte balance and plays an important physiological role in the long-term regulation of Na ϩ and K ϩ in the distal tubule and collecting duct. [1] [2] [3] [4] To date, several studies suggested that aldosterone plays a larger role than once appreciated in the regulation of vascular tone as well as in cardiovascular alterations such as endothelial dysfunction, vascular fibrosis, and inflammation, left ventricular hypertrophy, congestive heart failure, and cardiac arrhythmias. [5] [6] [7] [8] [9] [10] [11] [12] Furthermore, aldosterone has also been shown to be involved in the pathogenesis of hypertension. [13] [14] [15] In general terms, endothelial dysfunction is characterized by reduced endothelium-dependent relaxations, suggesting a reduced availability of NO attributable to a reduction of NO production or enhanced NO inactivation. 16, 17 In addition, an increased production of vasoconstrictor factors could be also responsible for the reduced endothelium-dependent relaxations. 13 Diminished endothelium NO synthase expression or activity has been proposed as an important mechanism leading to reduced NO availability and endothelial dysfunction in aldosterone-treated animals. 18 -20 Furthermore, enhanced vascular production of reactive oxygen species, specifically superoxide anions, has been reported as another important mechanism contributing to endothelial dysfunction in aldosterone-treated animals. 21, 22 However, the role of vasoconstrictor prostanoids prostaglandin F 2␣ (PGF 2a ) and thromboxane A 2 (TXA 2 ), as well as prostacyclin (PGI 2 ) and PGE 2 , which can act as vasoconstrictors under certain conditions, 23, 24 is not well established in the endothelial dysfunction produced by aldosterone. Thus, the aim of the present study was to analyze the possible involvement of endothelium-derived vasoconstrictors prostanoids on the reduced en- 
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Methods
Male 6-month-old Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) weighing 200 to 250 g were obtained from colonies maintained at the animal quarters of the Facultad de Medicina of the Universidad Autónoma de Madrid.
Rats were divided into 2 groups: untreated and aldosterone treated (0.05 mg/kg per day). Controlled time-release pellets (Innovative Research of America) containing aldosterone or vehicle were subcutaneously implanted. At the end of the treatment period (3 weeks), systolic blood pressure (BP) was measured by a tail-cuff method. After death by CO 2 
Endothelium-Dependent Relaxations
Thoracic aorta was cut transversally in ring segments (4-mm long). Each ring was placed inside a 5-mL heated bath filled with KHS (37°C) bubbled with a 95% O 2 -5%CO 2 mixture, pH 7.4, and suspended between 2 L-shaped stainless steel hooks. The top one was attached to a force transducer (Grass FTO3C); in turn, this was connected to a model 7D Grass polygraph for measurement of isometric tension. Rings were allowed to equilibrate for 90 minutes, with changes of buffer every 15 minutes and with several adjustments of length until baseline tension stabilized at 1 g to obtain comparable acetylcholine (ACh) relaxation in both strains. In previous studies, we found that 2 g but not 1 g of resting tension evidenced reduction of ACh relaxation in SHR compared with WKY. 25 When tension was stable, experiments were initiated by obtaining a reference contractile response to 75 mmol/L KCl. Endothelium-dependent relaxations were studied by evaluating relaxations to ACh (10 Ϫ10 to 10 Ϫ5 mol/L) in noradrenaline precontracted rings (1.5Ϯ0.18 g). In pilot studies, we found that treatment of rats with aldosterone reduced endothelium-dependent relaxation to ACh.
To investigate the possible participation of prostanoids in the reduction of ACh relaxations produced by aldosterone treatment, aortic segments from both strains were incubated with the cyclooxygenase-1 (COX-1)/COX-2 inhibitor indomethacin (10 Ϫ5 mol/L; Sigma-Aldrich). To clarify whether COX-1 or COX-2 was involved in the effect of aldosterone on ACh relaxation, aortic segments were incubated with the specific COX-2 inhibitor NS-398 (10 Ϫ5 mol/L; Calbiochem-Novabiochem GmbH). In another set of experiments, segments were incubated with SQ 29 548 (TP receptor antagonist; 10 Ϫ6 mol/L; ICN Iberica) to evaluate the possible participation of vasoconstrictor prostanoids. Finally, segments were incubated with the thromboxane (TXA 2 ) synthase inhibitor furegrelate (10 Ϫ6 mol/L; Sigma-Aldrich), the PGI 2 synthesis inhibitor tranylcypromine (TCP; 10 Ϫ5 mol/L; Sigma-Aldrich), or the cytochrome P450 inhibitor 1-aminobenzotriazole (ABZ; 5ϫ10 Ϫ4 mol/L; Sigma-Aldrich) to analyze the possible involvement of these prostanoids in the effect of aldosterone on ACh relaxations.
Western Blot Analysis
Aorta samples from control and aldosterone-treated WKY and SHR were homogenized in a boiling buffer composed of 1 mmol/L sodium vanadate (Sigma-Aldrich), 1% SDS and pH 7.4, 0.01 mol/L Tris-HCl, and protein content was measured with a DC protein assay kit (Bio-Rad). Homogenates containing 20 g protein were fractionated in a 10% SDS-PAGE and transferred to a polivinilifluoride membrane (Bio-Rad). Membranes were blocked in 5% nonfat milk in Tris-HCl buffered saline 0.1% Tween 20 (TBS-T). Subsequent washes were done in TBS-T, and the membranes were incubated with antibody against COX-2 (1:1000; Cayman Chemical) or ␣-actin (1:3000; Sigma-Aldrich) proteins and individual horseradish peroxidase-conjugated secondary antibodies in blocking buffer. Immunoreactive proteins were detected by chemiluminescence with ECLPlus (Amersham).
Prostanoid Production
To measure the release of PGE 2 and the metabolites of PGF 2␣, TXA 2 , PGI 2, 13,14-dihydro-15-keto PGF 2␣, thromboxane B 2 (TXB 2 ), and 6-keto-PGF 1␣ , we used PGE 2 enzyme immunoassay (EIA) KitMonoclonal, EIA kit, 13,14-dihydro-15-keto PGF 2␣ EIA kit (Cayman Chemical), TXB 2 immunoassay, and 6-keto-PGF 1␣ immunoassay (R & D Systems), respectively. Segments of rat aorta arteries were preincubated for 30 minutes in 5 mL of KHS at 37°C and continuously gassed with a 95% O 2 -5% CO 2 mixture (stabilization period). Afterward, 2 washout periods of 7 minutes in a bath of 0.3 mL of KHS were made before incubation with ACh (10 Ϫ10 to 10 Ϫ5 mol/L). The different assays were made following manufacturer instructions. Results were expressed as pg prostanoid/mL mg tissue.
Statistical Analysis
Results are expressed as meanϮSEM of the number of rats indicated. Differences were analyzed using Student t test for unpaired experiments or 2-way ANOVA to compare groups. A P value Ͻ0.05 was considered significant.
Results

Blood Pressure
As expected, SHR presented higher BP levels than WKY (175Ϯ3.2 versus 115Ϯ2.8 mm Hg; PϽ0.05). Chronic aldosterone administration did not substantially modify BP levels in any strain (SHR 181Ϯ6; WKY 121Ϯ7.9). Figure 1A and 1B) . Incubation of aortic rings with indomethacin or the COX-2 inhibitor NS-398 enhanced (PϽ0.05) ACh relaxations in both strains treated with aldosterone in a comparable manner (Figure 2A and 2B) . Incubation with SQ 29 548 or ABZ also increased (PϽ0.05) ACh relaxations in both strains treated with aldosterone in a comparable manner ( Figure 3A and 3B) . However, incubation with the thromboxane synthase inhibitor furegrelate did not modify endothelium-dependent relaxations in any group treated with aldosterone ( Figure 3A and 3B). Incubation with PGI 2 synthesis inhibitor TCP increased (PϽ0.05) ACh relaxations in both strains treated with aldosterone ( Figure 3A and 3B), this enhancement being higher in SHR.
Endothelium-Dependent Relaxations
COX-2 Protein Expression
COX-2 protein expression was higher in aortic segments from SHR compared with WKY. In both rat strains, this parameter was increased after chronic aldosterone treatment (Figure 4 ).
Prostanoid Production
In normotensive animals, aldosterone increased AChstimulated aortic production of 13,14-dihydro-15-keto PGF 2a, PGE 2 , and 6-keto-PGF 1␣ (Figure 5A through 5C; PϽ0.05) and did not modify TXB 2 levels (untreated 68Ϯ14 pg/mL mg tissue; aldosterone 78Ϯ11 pg/mL mg tissue). However, in SHR, aldosterone did not modify 13,14-dihydro-15-keto PGF 2␣ (untreated 1.5Ϯ0.3 pg/mL mg tissue; aldosterone 1.2Ϯ0.2 pg/mL mg tissue); PGE 2 (untreated 8Ϯ0.4 pg/mL mg tissue; aldosterone 8.3Ϯ0.8 pg/mL mg tissue), and TXB 2 release (untreated 185Ϯ21 pg/mL mg tissue; aldosterone 179Ϯ33 pg/mL mg tissue) but increased the 6-keto-PGF 1␣ production induced by ACh ( Figure 5D ; PϽ0.05). Treatment with aldosterone increased 6-keto-PGF 1␣ levels in a similar extent in segments from both strains (WKY 1.83Ϯ0.23; SHR 1.89Ϯ0.3).
Discussion
The present results show that in our experimental conditions, aldosterone alters endothelial function because its chronic administration diminished the ACh-induced relaxation in normotensive and hypertensive animals. These data confirm previous observations indicating that aldosterone was able to produce endothelial dysfunction in experimental and clinical studies. 20, 26, 27 This effect appears to be independent of previous BP levels because the reduction in ACh relaxation was similar in normotensive and hypertensive rats. Moreover, this deleterious effect induced by aldosterone on endothelial function is not mediated by hemodynamic changes induced by this mineralocorticoid because no differences in BP levels were observed between treated and untreated animals in both strains. Because an increase in BP associated with aldosterone administration has been reported, 7, 15 the lack of effect observed in this study could be a consequence of differences in experimental conditions (dose and period treatment).
Several mechanisms have been implicated in the endothelial dysfunction associated with different pathological situations (hypertension, diabetes, aging, and hypercholesterolemia) 17,18,28 -30 including a reduced NO availability and an increase in vasoconstrictor factors. 28, 29, 31, 32 Similarly, in aldosterone-treated animals, decreased NO levels have also been implicated in the alteration of endothelial function, mainly because of an increase in oxidative stress. 22 In addition, the present results show that arachidonic acidderived vasoconstrictor prostanoids are involved in endothelial dysfunction produced by aldosterone treatment in normotensive and hypertensive rats. This is demonstrated by the normalization of ACh relaxation in aortic segments of aldosterone-treated rats in the presence of the COX-1/COX-2 inhibitor indomethacin. Because the presence of the specific COX-2 inhibitor NS 398 increased the ACh response in a similar extent, then indomethacin, the vasoconstrictor factors are derived from COX-2. Supporting this role is the observation that COX-2 is overexpressed in the aorta from aldosterone-treated animals in normotensive and hypertensive rats, reaching higher levels in SHR. This is in agreement with a previous study showing that the aldosterone antagonist eplerenone was able to reduce COX-2 expression in hearts from rats treated with angiotensin II and a high-salt diet. 33 Therefore, the data suggest that there are interactions between aldosterone and COX that can be relevant in the regulation of vascular function.
It has been reported that through the activation of TP receptors, vasoconstrictor prostanoids such as TXA 2 can participate in the endothelial dysfunction associated with different cardiovascular risk factors. 30, 32, 34 Incubation with SQ 29 548, a TP receptor antagonist, increased ACh relaxations in both strains of rats treated with aldosterone in a comparable manner, suggesting the participation of vasoconstrictor prostanoids through TP receptors. However, the present results showed that in aorta from WKY and SHR treated with aldosterone, TXA 2 is not an important candidate responsible for the reduction of endothelium-dependent relaxations. This affirmation is based on the fact that the thromboxane synthase inhibitor furegrelate did not modify this response in any strain. These data are in agreement with previous results indicating that ACh did not release TXA 2 in aorta from normotensive and hypertensive rats. 23, 35 Likewise, ACh was unable to increase TXA 2 release in aorta from aldosterone-treated animal. Consequently, the participation of other prostanoids such as PGF 2␣ , PGE 2 , and PGI 2 , which can be synthesized through COX-2 and can act as vasoconstrictors under certain conditions, 23, 24 can be proposed. The present results showed that the presence of PGI 2 synthesis inhibitor TCP was able to increase the reduced ACh relaxation in both strains, although it was only normalized in SHR. Moreover, aldosterone increased aortic production of 6-keto-PGF 1␣ induced by ACh in both strains.
Therefore, it seems that PGI 2 plays a major role in the alterations in endothelial function produced by aldosterone in normotensive and hypertensive conditions, supporting that the vasoconstrictor action of PGI 2 observed 23, 24, 36, 37 could be relevant in hyperaldosteronism. TP receptor could be the main receptor implicated in this vasoconstrictor action of PGI 2 because SQ 29 548 increased ACh relaxation in aorta from both strains treated with aldosterone. However, PGI 2 or a metabolite of PGI 2 would activate EP 1 or EP 3 receptors that are coupled to contraction in vascular smooth muscle. In this sense, it has been described that EP 1 and EP 3 receptors bound IP ligands such as iloprost with K i values comparable to those for IP receptor. 38, 39 In addition, the participation of vasoconstrictor derivated from cytochrome P450 family can also be proposed because the presence of the cytochrome P450 inhibitor ABZ reversed the alterations in ACh relaxation in both strains. 40 Because PGI 2 synthase is a member of the P450 family, 38 it could be postulated that the effect of ABZ is mediated by PGI 2 synthesis inhibition.
It should be mentioned that under normotensive conditions, besides PGI 2 , other vasoconstrictor prostanoids such as PGF2 ␣ and PGE 2 seem to participate in the reduced AChinduced relaxations, as demonstrated by the results on prostanoid release. These differences could explain why endothelial dysfunction is comparable in both strains in addition to the higher expression of COX-2 in SHR.
In conclusion, the results of the study demonstrated that chronic treatment with aldosterone was able to produce endothelial dysfunction through COX-2 activation in normotensive and hypertensive conditions. PGI 2 seems to be the main factor accounting for endothelial dysfunction in hypertensive rats, whereas other prostanoids besides PGI 2 appear to be involved in endothelial dysfunction under normotensive conditions.
Perspectives
Aldosterone has been involved in vascular damage recently through direct effects on vascular wall at several levels (hypertrophy, inflammation, fibrosis, endothelial dysfunction, and atherosclerosis). The present results showed that vasoconstrictor prostanoids account for endothelial dysfunction induced by aldosterone in rats. Because endothelial dysfunction is involved in the development and complications of atherosclerosis, it could be hypothesized that treatment with anti-inflammatory drugs, and specifically COX-2 inhibitors, could ameliorate vascular damage and progression of atherosclerosis in patients with elevated aldosterone production. Figure 5 . Effect of aldosterone treatment on the production of 13,14-dihydro-15-keto PGF 2a (A), PGE 2 (B), and 6-keto-PGF 1␣ (C) in aortic segments from WKY and on the production of 6-keto-PGF 1␣ in aortic segments from SHR (D).
